Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had on ensuring the supply of lisdexamfetamine.

We are aware of supply issues affecting medicines used for the management of attention deficit hyperactivity disorder (ADHD), including lisdexamfetamine. We have issued communications, in the form of a National Patient Safety Alert, to the National Health Service to advise healthcare professionals on management of patients during this time. We continue to work closely with manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom.

The shortage of lisdexamfetamine capsules is not confined to the UK, it is a global issue and other markets are affected. We have added ADHD products, including lisdexamfetamine, to the export restriction list to protect available supplies for UK patients. We anticipate that the supply disruption will resolve at various dates between October and December 2023.